Table 2.

Baseline demographic and biochemical parameters and history of kidney disease by treatment groupa

ParameterControl(n = 65)Intravenous Iron(n = 64)
Age (yr)58.7 ± 15.261.2 ± 13.0
Women (n [%])37 (56.9)27 (42.2)
Weight (kg)75.0 ± 22.376.4 ± 21.0
Height (cm)168.1 ± 9.8171.9 ± 36.1
Race (n [%])
    white20 (30.8)20 (31.3)
    black33 (50.8)30 (46.9)
    Hispanic9 (13.8)9 (14.1)
    Asian/Pacific Islander2 (3.1)5 (7.8)
    other1 (1.5)0 (0.0)
Hemodialysis access (n [%])
    AV fistula30 (46.2)33 (51.6)
    AV graft21 (32.3)20 (31.3)
    temporary catheter3 (4.6)2 (3.1)
    permanent catheter11 (16.9)9 (14.1)
Dialysis vintage (yr)4.2 ± 3.15.1 ± 5.0
WBC (1000/mm3)6.3 ± 2.37.5 ± 2.6
MCV (mcm3)94.8 ± 9.095.6 ± 7.7
MCH (pg/cell)30.0 ± 3.230.1 ± 2.8
Most recent Kt/V1.7 ± 0.31.6 ± 0.4
Serum albumin (g/dl)3.7 ± 0.43.8 ± 0.4
CRP (mg/L)b25.5 ± 29.329.3 ± 39.2
Intravenous iron in previous 4 wk (n [%])24 (36.9)22 (34.4)
Intravenous iron given in previous 4 wk (mg)70 ± 10861 ± 103
Epoetin dosage (IU/wk)35,128 ± 17,76933,498 ± 17,377
  • a There were no statistically significant differences between the two groups in any of the baseline demographic and biochemical characteristics or history of kidney disease. AV, arteriovenous.

  • b CRP values were obtained using the high-sensitivity assay.